Targeting specific pathways to reduce nerve damage from chemotherapy
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
This study is looking at ways to help ovarian cancer patients who are experiencing tough side effects from chemotherapy, like trouble thinking and nerve pain, by testing a new treatment that could protect their nerves and make them feel better during and after their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11059725 on NIH RePORTER |
What this research studies
This research investigates how certain pathways in the nervous system can be targeted to reduce the harmful effects of chemotherapy, specifically cisplatin, which is commonly used to treat ovarian cancer. Many patients experience debilitating side effects such as cognitive impairment, neuropathy, and gait changes after treatment. The study aims to explore the use of small molecule inhibitors to prevent nerve damage and improve quality of life for patients undergoing chemotherapy. By understanding the mechanisms behind these side effects, the research seeks to develop potential interventions that could alleviate these issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are women undergoing treatment for ovarian cancer who are experiencing chemotherapy-related cognitive impairment or peripheral neuropathy.
Not a fit: Patients who are not receiving cisplatin or those who do not experience nerve-related side effects from chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life for cancer patients experiencing nerve-related side effects from chemotherapy.
How similar studies have performed: Previous research has shown promise in targeting similar pathways to mitigate nerve damage from chemotherapy, indicating that this approach could be effective.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Bota, Daniela Annenelie — University of California-Irvine
- Study coordinator: Bota, Daniela Annenelie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.